Shares of PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) traded down 0.5% on Friday . The company traded as low as $0.6874 and last traded at $0.6965. Approximately 53,074 shares changed hands during trading, an increase of 501% from the average daily volume of 8,831 shares. The stock had previously closed at $0.70.
PharmaCyte Biotech Trading Down 4.1%
The firm has a 50-day simple moving average of $0.75 and a 200 day simple moving average of $0.75.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical?stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose?based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
See Also
- Five stocks we like better than PharmaCyte Biotech
- Why Wall Street Suddenly Sees SpaceX as an AI Company
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
